Abstract

Conventional photodynamic diagnosis (PDD) and therapy (PDT) makes use of photosensitizers that are excited by continuous light irradiation of specific wavelengths. In the case of PDT, the overdose of continuous excitation may lead to an expansion of necrosis in cancer cells or morbidity in healthy surroundings. The present study involves 5-h fluorescence imaging of living human lung epithelial carcinoma cells (A549) in the presence of a novel photosensitizer, PVP-Hypericin (PVP: polyvinylpyrrolidone) to optimize the excitation light doses for PDD and PDT. A number of time-lapse imaging experiments were performed using a low-power blue LED operating in either continuous or pulsed mode. The irradiances I* were 1.59, 6.34 and 14.27mW/cm2, the pulse lengths L being 0.127, 1.29, 13, 54.5, 131 and 60,000ms. Then, the relation between irradiance, various exposure times, photobleaching and phototoxicity of PVP-Hyperycin was investigated. Results showed a nonlinear relationship between the amounts of excitation dose, cell viability and toxicity. For all experimental I*, minimal phototoxicity and photobleaching was detected when cells were exposed to brief pulses of light (L⩽13ms). On the other hand, pulsed excitation with I*=14.27mW/cm2 and L=131ms induced high percentages of apoptosis comparable to the long exposures of L=60,000ms and the continuous excitation. Thus, replacement of continuous excitation by a pulsed method seems applicable for PDT.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.